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This study assesses knowledge, attitudes, and behavioural intention towards human papillomavirus (HPV) infection and vaccination in
a random sample of 1348 adolescents and young women aged 14–24 years in Italy. A self-administered anonymous questionnaire
covered demographics; knowledge about HPV infection, cervical cancer, and HPV vaccine; the perceived risk for contracting HPV
infection and/or for developing cervical cancer, the perceived benefits of a vaccination to prevent cervical cancer, and willingness to
receive an HPV vaccine. Only 23.3% have heard that HPV is an infection of the genital mucosa and about cervical cancer. Those
older, with at least one parent who is a health care professional, with personal, familiar, or friendly history of cervical cancer, and
having underwent a health checkup in the last year with information about HPV vaccination were significantly more knowledgeable.
Risk perception scores (range: 1–10) of contracting HPV infection and of developing cervical cancer were 5.8 and 6.5. Older age, not
having a parent who is a health care professional, having had a personal, familiar, or friendly history of cervical cancer, and need of
additional information were predictors of the perceived susceptibility of developing cervical cancer. The vast majority professed intent
to receive an HPV vaccine and the significant predictors were having at least one parent who is a health care professional, a high
perceived risk of contracting HPV infection and of developing cervical cancer, and a high belief towards the utility of a vaccination for
preventing cervical cancer. Knowledge about HPV infection and cervical cancer should be improved with more attention to the
benefit of HPV vaccination.
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Human papillomavirus (HPV) is one of the most common sexually
transmitted infections in sexually active adolescent girls and young
women of several economically developed countries (Richardson
et al, 2003; Syrja ¨nen et al, 2005; Kitchener et al, 2006; Dunne et al,
2007). Strong evidence has been observed for the role of persistent
high-risk HPV types (16 and 18), in the aetiology of cervical
cancer, as worldwide they are responsible for approximately 70%
of all cases (Clifford et al, 2006; Markowitz et al, 2007). Cervical
cancer is the second most common cancer among women
worldwide, with half a million who develop it annually and more
than half of the cases die as a result (Parkin et al, 2005; Cutts et al,
2007).
Highly immunogenic and safe HPV vaccines recently have been
licensed for use, the first explicitly designed to prevent cancer
induced by a virus, which can reduce the morbidity and mortality
of cervical cancer by offering protection to HPV types 16 and 18.
Because the vaccine has the maximum benefit when given before a
person becomes sexually active, the Advisory Committee on
Immunization Practices of the Centers for Disease Control and
Prevention (CDC) and the American Academy of Pediatrics, have
recommended routine vaccination for girls aged 11 or 12 years
(Clifford et al, 2006; American Academy of Pediatrics, 2007). In
Italy, the Ministry of Health has recently approved a national
programme for free HPV vaccination for girls aged 12 (Ministero
della Salute, 2007).
Widespread acceptance of HPV vaccine is likely to provide
enormous public health benefits (Garnett et al, 2006; Bosch et al,
2008; Goldhaber-Fiebert et al, 2008) and it must be administered
before initiating sexual activity (Stanley et al, 2006; Markowitz
et al, 2007; Saslow et al, 2007) and hence would be most effective if
offered during early adolescence (Adams et al, 2007; Cutts et al,
2007). Because most sexually active individuals will become
exposed to the virus throughout their lives and because the HPV
vaccine is available, it is extremely important to gather data on
HPV infection and vaccination. Such questioning has already
taken place in several studies which mainly address vaccine
acceptability among parents (Olshen et al, 2005; Brabin et al, 2006,
2007; Dempsey et al, 2006; Dinh et al, 2007; Marlow et al, 2007)
and health care workers (Kahn et al, 2003, 2005; Aldrich et al, 2005;
Riedesel et al, 2005; Moreira et al, 2006a,b; Duval et al, 2007;
Hopenhayn et al, 2007; Waller et al, 2007; Woodhall et al, 2007),
but very little research has targeted adolescents. Therefore, this
study attempts to generate information about knowledge, atti-
tudes, and behavioural intention towards HPV infection and
vaccination among adolescents and young women in Italy. Revised 9 May 2008; accepted 9 May 2008
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sMATERIALS AND METHODS
This cross-sectional investigation was conducted from March
through May 2007 and the target population comprised 1348
women aged 14–24 years. The sample was selected with a two-
stage cluster method. Seven faculties that cover a wide range of
disciplines (economics, education, law, literature, and sport
sciences) in two Universities and six public secondary schools in
the geographic area of the Campania region, in the South of Italy,
were randomly chosen. A simple random technique was adopted in
selecting students from each faculty and school.
Before the study, a meeting with the Head and the Dean of each
randomly selected school and faculty was arranged to present the
project and the permission and collaboration were obtained. A
questionnaire was pilot tested on 25 students before initiation of
the survey, the objective of which was to identify the basic
questions most valid for testing the comprehensiveness and
relevance of our terms. As part of the process of informed
consent, all potential candidates were invited to participate
through a letter containing information about purpose and
objectives, also indicating that participation in the survey was
voluntary, and that privacy and confidentiality would be strictly
protected as no personal identifiers were included in the
questionnaire and data would be presented only in an aggregated
manner. For those under 18 years of age, a separate information
letter was addressed to the parents. These policies were also
printed explicitly on the front page of the questionnaire. Provided
that respondent and parental consent were obtained, data were
collected by self-administered anonymous structured question-
naire administered with a reply envelope. The questionnaires were
delivered to students in their classroom one time and were
completed at the time of distribution. A respondent’s consent was
taken into account while filling the questionnaire. The ques-
tionnaire was used to explore several topics, including: (1) student
characteristics, included age, marital status, employment status,
whether they were living alone or not, and whether they have had a
personal, familiar, or friendly history of cervical cancer; (2)
knowledge about HPV infection (definition and modes of
transmission), cervical cancer (definition and preventive mea-
sures), and availability of an HPV vaccine; (3) attitudes pertaining
to assess whether or not the respondent perceived a risk for
contracting HPV infection and/or for developing cervical cancer,
opinions about the perceived benefits of a vaccination to prevent
cervical cancer, and their willingness to receive an HPV vaccine;
(4) behaviour, included questions whether or not respondents have
ever had sex, age at first sex, number of acts of intercourse and of
partners in the last year, and how frequently they were protected
by condoms during intercourse with the partner(s) in the last year;
health-promoting behaviour was assessed with questions about
how often the respondent underwent a health checkup in the last
year, whether respondents’ health care provider informed them
about HPV vaccine, and whether they have received the HPV
vaccine; (5) sources of and needs of information regarding HPV
vaccine and cervical cancer.
For items regarding their knowledge, participants were asked to
provide answers with options for ‘no’, ‘do not know’, and ‘yes’. All
attitudes were measured on a 10-point Likert scale with a score
ranging from 1 to 10. The responses for the two questions about
perceived risk were recorded as 1 for no risk at all and 10 for very
high perceived risk; for the perceived benefits of a vaccination to
prevent cervical cancer, 1 for not at all and 10 for high utility; and for
their willingness to receive HPV vaccine, 1 for unwillingness and 10
for willingness. The respondents were also asked to report directly
reason(s) for willingness or unwillingness to receive HPV vaccine.
Questions pertaining to behaviours were close ended with nominal or
categorical (yes or no) responses; the frequency of the use of condoms
in the last year was measured on a five-point Likert scale ranging from
‘never’ to ‘every time’. Ethics committee approval was obtained.
Statistical analysis
We analysed multivariable logistic and linear regression models
using a forward stepwise procedure to assess the independent
predictors of the following outcomes of interest: have heard about
HPV infection and cervical cancer (Model 1); perception of risk of
developing cervical cancer (Model 2); willingness to receive an
HPV vaccine (Model 3). The following explanatory variables were
included in all models: age (continuous), at least one parent is a
health care professional (0¼no, 1¼yes), personal, familiar, or
friendly history of cervical cancer (0¼no, 1¼yes), at least a health
checkup in the last year and the physician informed them about
HPV vaccination (0¼no, 1¼yes), number of sexual partners in
the last year (0¼0, 1¼1, 2¼X2), and need of information about
HPV vaccination and cervical cancer (0¼no, 1¼yes). The
following variables were also included: have already heard about
HPV infection and cervical cancer (0¼no, 1¼yes) in Models 2
and 3; perception of risk of contracting HPV infection (con-
tinuous), perception of risk of developing cervical cancer
(continuous), and perceived benefits of a vaccination to prevent
cervical cancer (continuous) in Model 3. The significance level for
variables entering the logistic and linear regression models was set
at 0.2 and for removing at 0.4. Odds ratios (ORs) with 95%
confidence intervals (CIs) were used in the logistic regression
analyses. All reported P-values were assessed using two-sided tests
and statistical significance was taken as a cutoff of Pp0.05
throughout. The statistical package Stata (Version 8.1) was used
for the analysis (Stata Corporation, 2003).
RESULTS
Subjects who participated in the survey were 1341 and a response
rate of 99.5% was achieved. The mean age of participants was 19
years, almost all were single, the majority was full-time students,
8.9% had at least one parent who is a health care professional, and
16.3% has had a personal, familiar, or friendly history of cervical
cancer.
The distribution of respondents who answered correctly to each
of the different items of the knowledge about HPV infection and
cervical cancer are presented in Table 1. Less than one-third
(29.8%) reported that they have heard that HPV is one of the most
common infections of the genital mucosa and three-quarters of
them identified that the infection is primarily transmitted through
sexual intercourse. Only half reported having heard of cervical
cancer before and 60.2 and 34.8% of them, respectively, know that
the majority of cases and deaths can be prevented through
detection of precancerous changes in the cervix by using the Pap
test and that condom use reduce the risk for HPV and cervical
cancer. Less than half (42.1%) knows that the vaccine was a
preventive measure, but only 15.3% knows that a vaccine is
available in Italy. Overall, only 23.3% have heard that HPV is one
of the most common infections of the genital mucosa and about
cervical cancer. The adjusted ORs for the likelihood of having
heard about HPV infection and cervical cancer by several variables
are presented in Table 2. After multivariate logistic adjustments,
this model reveals that older age was significantly associated with
the outcome as the adjusted OR was 1.14 (95% CI 1.08–1.2) for
every 1-year increment. This model also reveals that female
subjects having at least one parent who is a health care
professional (OR¼1.66; 95% CI 1.07–2.58), having had a personal,
familiar, or friendly history of cervical cancer (OR¼3.04; 95% CI
2.26–5.11), and having underwent a health checkup in the last year
and the physician informed them about HPV vaccination
(OR¼2.44; 95% CI 1.23–4.85) were associated with having higher
odds of having heard about HPV vaccination compared to those
who have not (Model 1 in Table 2).
Risk perception of contracting HPV infection and of developing
cervical cancer was similar with the respondents inferring a
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slevel of perception with scores of 5.8 and 6.5, respectively and only
12.7 and 19.9% perceived themselves at a high risk, respectively by
responding ‘10’. Table 2 presents the adjusted mean of perceived
risk from a multiple linear regression model that controlled for the
contribution of several variables. Older age, not having at least one
parent who is a health care professional, having had a personal,
familiar, or friendly history of cervical cancer, and need of
additional information about this cancer and HPV vaccination
were significantly the predictors of the perceived susceptibility of
developing cervical cancer (Model 2 in Table 2). Subjects were
asked about their belief towards the utility of an HPV vaccination
for preventing cervical cancer and whether they would consider it
in future, with a mean total score of 8.7 and 7.7, respectively. The
vast majority (81.7%) professed intent to obtain an HPV vaccine in
future. Multiple logistic regression was used to examine the
probability of willingness to receive the HPV vaccination and the
adjusted ORs are presented in Table 2. The significant predictors
of the willingness to receive this vaccine were high perceived risk
of contracting HPV infection (OR¼1.18; 95% CI 1.08–1.29) and of
developing cervical cancer (OR¼1.09; 95% CI 1.01–1.18), a high
belief in the utility of a vaccination for preventing cervical cancer
(OR¼1.33; 95% CI 1.24–1.42), and having one parent who is a
health care professional (OR¼1.86; 95% CI 1.03–3.39; Model 3 in
Table 2).
For those who stated that they would consider the HPV
vaccination in future, the main reasons were the belief that the
vaccination reduces the risk of contracting HPV infection (73.8%)
and of developing cervical cancer (59.7%), and felling at risk
(10%). By contrast, for those who stated that they would not
consider HPV vaccine, the most common reasons were the belief
that the vaccine was dangerous (59.6%) and that they feel to be not
at risk (42%).
According to sexual behaviour pattern, 45.4% reported current
or previous sexual activity, and the mean age of first sexual
intercourse of the sexually experienced was 17 years. Overall, only
27.1% of those sexually experienced reported that they have always
used a condom during the intercourse in the last year.
Approximately, half had at least one health checkup over the last
year (48%) and for only 3%, the physician informed them about
HPV vaccination.
When asked about their main source of information of HPV
infection and cervical cancer, only 6% claimed health profes-
sionals. Among those who knew that a vaccine is available in Italy,
62.7 and 17.4% had received such information from television/
mass media and from health professionals, respectively. Almost all
respondents wanted more information about HPV vaccination
(94.4%) and cervical cancer (95.7%).
Table 1 Knowledge about HPV and cervical cancer of the study
population
N %
Have heard about HPV infection 399 29.8
Have heard about cervical cancer 706 52.6
Correct response
N %
Modes of transmission of HPV
a
Complete sexual intercourse (true) 300 75.2
Incomplete sexual intercourse (true) 116 29.1
Needle sharing (false) 91 22.9
Pregnancy (false) 70 17.5
Vaginal delivery (true) 63 15.8
Preventive measures for cervical cancer
b
Pap test (true) 425 60.2
Late start of sexual activity (true) 299 42.4
HPV vaccination (true) 297 42.1
Oral contraceptive (false) 256 36.3
Condom use (true) 246 34.8
HPV¼human papillomavirus.
aOnly for those who reported that they have heard
about HPV infection.
bOnly for those who reported that they have heard about
cervical cancer.
Table 2 Logistic and linear regression models’ results
Variable OR SE 95% CI P
Model 1. Have heard about HPV infection and cervical cancer. Log-likelihood¼ 648.78, w
2¼104.86 (5 df), Po0.0001
Age 1.14 0.03 1.08–1.2 o0.001
Personal, familiar, or friendly history of cervical cancer 3.4 0.71 2.26–5.11 o0.001
Health checkup in the last year and the physician informed about HPV vaccination 2.44 0.86 1.23–4.85 0.011
At least one parent who is a health care professional 1.66 0.37 1.07–2.58 0.024
Number of sexual partners in the last year 1.24 0.14 0.99–1.55 0.062
Model 3. Willingness to receive an HPV vaccine. Log-likelihood¼ 525.25, w
2¼172.93 (6 df), Po0.0001
Perception of risk of contracting HPV infection 1.18 0.05 1.08–1.29 o0.001
Perceived benefits of a vaccination to prevent cervical cancer 1.33 0.05 1.24–1.42 o0.001
Perception of risk of developing cervical cancer 1.09 0.04 1.01–1.18 0.03
At least one parent who is a health care professional 1.86 0.57 1.03–3.39 0.041
Health checkup in the last year and the physician informed about HPV vaccination 2.92 1.7 0.93–9.16 0.065
Number of sexual partners in the last year 0.88 0.11 0.69–1.12 0.291
Variable Coefficient SE tP
Model 2. Perception of risk of developing cervical cancer. F (5,1281)¼8.98, Po0.0001, R
2¼3.4% adjusted R
2¼3%
Need of information about cervical cancer and HPV vaccination 1.66 0.36 4.54 o0.001
Age 0.06 0.02 2.61 0.009
Personal, familiar, or friendly history of cervical cancer 0.59 0.27 2.16 0.031
At least one parent who is a health care professional  0.53 0.26  2.02 0.043
Have heard about cervical cancer 0.2 0.16 1.25 0.212
Constant 3.55
CI¼confidence interval; HPV¼human papillomavirus; OR¼Odds ratio; SE¼standard error.
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sDISCUSSION
This large study expands the previous reports and findings on
knowledge, attitudes, and behaviour towards HPV infection,
vaccination, and cervical cancer patterns among young women
are of particular interest, because the responses reflect real issues
in this population setting. This study included only women, mainly
because when it has been conducted, the available HPV vaccine
was approved for use in female subjects only and, as already
indicated, international guidelines recommend vaccination of girls
aged 11–12 years and in our country, it was free of charge only for
girls of 12 years of age. Moreover, this approach is supported by
cost–effectiveness analyses that have indicated that the additional
vaccination of boys has a limited effect compared to girls-only
vaccination (Taira et al, 2004; Newall et al, 2007).
Our results indicate that women’s knowledge about HPV
infection and cervical cancer was remarkably poor, as only
23.3% ever heard of them; particularly striking was that a very
high proportion did not know that vaccination can prevent this
cancer and that they were unaware of such a vaccine in Italy. This
finding was lower than those observed in earlier surveys. Indeed,
33% of 397 adolescents, mean age of 15 years in Finland, have
heard of HPV before addressing the questionnaire (Woodhall et al,
2007) and 58% of 811 university students in the United Kingdom
have heard of HPV (Waller et al, 2007). Moreover, our prevalence
that 75.2% knew about sexual transmission of HPV is higher than
the 66.7% found in a study of 204 women aged 16–23 years
attending a public outpatient gynaecological clinic in Brazil
(Moreira et al, 2006a). As in these prior studies, our results
suggest that the continued efforts are urgently needed to educate
young women. As predicted, the concept of physician influence is
clearly important in this context of educating and counselling
patients and potentially it is at this level of initial contact between
physician and patient when interventions designed to increase
knowledge about HPV and cervical cancer might be best
implemented. Having a physician visit for a checkup and
information about HPV vaccination was an important predictor
of a higher level of knowledge and it is also not surprising that we
observed an association, although not reaching statistical sig-
nificance, between the willingness to receive the vaccination and
information from a physician. Indeed, there is a group of
respondents who consider HPV vaccination in future simply if
their physician engaged them in a discussion about HPV vaccine.
However, if patients remain uneducated about the opportunities,
then logically compliance and adherence with recommended
vaccination will stay forever low. So it is reasonable that an
endorsement from a trusted physician would most likely result in
acceptance of HPV vaccination now that guidelines are in place
and the vaccination is more popular.
Our study highlights the positive attitude of the sample, as a vast
majority (81.7%) professed intent to receive the HPV vaccination.
This finding is consistent with the already mentioned study in
Finland where 86% declaring they would accept the vaccination
(Woodhall et al, 2007); with a study in the United States, with 85%
of participants 18–30 years of age, recruited from the community
and clinical sites, who reported that they would be extremely or
very likely to receive an HPV vaccine (Kahn et al, 2003). A lower
value was reported in Brazil with 72% who would enroll in an HPV
vaccine trial (Moreira et al, 2006a). Finally, in a population-based
study in two Appalachian Kentucky counties, 92.1% of women
aged 18–29 years indicated an interest in HPV vaccination
(Hopenhayn et al, 2007).
Study participants showed that 12.7 and 19.9%, respectively,
perceived themselves likely to acquire the infection and the disease
by responding ‘10’. In the already mentioned studies of Brazil and
United States, 68.1% perceived themselves at moderate-to-high
risk (Moreira et al, 2006b) and 54% strongly or somewhat agreed
that they were at risk of developing cervical cancer (Kahn et al,
2003). Further, the results of the logistic regression model showed
that women who perceived a high risk of contracting HPV
infection were more likely to receive the vaccination in future. That
finding of an association between willingness to receive the
vaccination and self-perceived risk of contracting infection agrees
with a prior study (Moreira et al, 2006a). Why persons at higher
self-perceived risk are the most willing to obtain vaccination is
clear. Perceptions of heightened risk do serve as an effective
stimulus to pursue vaccination. Another notable finding was that
among the respondents who stated that they would not consider
HPV vaccination in future, their most commonly stated reason
appeared to be the belief that the vaccine was dangerous. These
findings have implications for practice in public health as
physicians, mainly those in primary care, are obligated to evaluate
and rectify, when appropriate, any misperceptions or confusions
about vaccination.
This study has some potential limitations. First, the research
questions were investigated by a cross-sectional study design. Such
design precludes determination of causal relationships between
different factors and outcomes. Second, information was gathered
by self-reported questionnaire and so the possibility exists that
some responses may have reported incorrect information.
Notwithstanding this criticism, the anonymity of the study may
have reduced the variation in the responses. This study, however,
displays important strengths: first, it provides information from a
large number of participants and this allows exploration of very
weak associations between variables; second, the data were
essentially complete; third, the participation rate was very high,
probably reflecting heightened interest for this survey.
In conclusion, our results suggest that the continuing efforts
should be directed at focusing attention towards the benefits of
following HPV vaccination recommendations emphasising those
factors positively associated. There is also an urgent need for
designing educational interventions to improve the level of
knowledge about HPV infection and cervical cancer.
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